Châtillon, France, September 29, 2026 The BLA is supported by the results from the successful Phase 3 VITESSE trial – the largest immunotherapy clinical trial to date for this population. DBV has requested Priority Review of the BLA. DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN Peanut Patch in Children Aged 4-7 Years DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced ...